ERBB2 and breast carcinoma: In this study, we have enrolled patients with HER2-positive left breast cancer undergoing hypofractionated adjuvant left-breast radiotherapy concomitantly with anti-HER2 therapy: trastuzumab, a combination of trastuzumab and pertuzumab or trastuzumab emtansine (T-DM1).